| |
Newsroom /
Industry
/
Industry
/
Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
The Testicular Cancer Therapeutics Market is Forecast to Show Gradual Growth
Until 2017
Hyderabad,
AP,
India
(prbd.net)
31/05/2011
GlobalData estimates that the global testicular cancer therapeutics market was valued at $91m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 3.8% over the next seven years, to reach $118m by 2017. The gradual growth of the market is primarily attributed to the expected continued domination of generics in the testicular cancer therapeutics market, as no disease-modifying molecule is expected to launch during the forecast period to 2017.
The global testicular cancer therapeutics market is attractive, with high unmet need. The unmet need in the market is around 49%, which is approximately valued at $45m. The testicular cancer pipeline is weak, with no molecules in the late stage of clinical development. The testicular cancer therapeutics market is not expecting the launch of any molecule in the near future, suggesting that the unmet need will remain high during the forecast period.
Testicular cancer is a market that is underserved by currently marketed drugs, mainly in terms of safety issues (serious adverse events). The market therefore provides opportunity for the entrants with better efficacy and safety profiles, which have a novel mechanism of action.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Testicular-Cancer-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
GlobalData’s analysis found that the testicular cancer therapeutic pipeline is weak. The therapeutics pipeline for testicular cancer consists of only three molecules in various stages of clinical development. Two molecules are in Phase II and one is in Phase I. Currently, no molecule is in late stages of clinical development. Moreover, the participation of companies in clinical trials for testicular cancer is not significant.
Generic products are likely to remain as the strong players in the testicular cancer therapeutics market. This is largely due to the fact that currently no molecules are present in the late stages of clinical development for the treatment of testicular cancer. This indicates that the unmet need is likely to remain high and the market is estimated to show a gradual growth during the forecast period to 2017.
GlobalData, the industry analysis specialist, has released its new report, “Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global testicular cancer market. The report identifies the key trends shaping and driving the global testicular cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline
products within the global testicular cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Testicular-Cancer-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|